Key findings reported in RET fusion-positive NSCLC include a 64% ORR of 105 consecutively enrolled and pre-treated patients, with a median duration of almost 18 months; for untreated NSCLC patients, an 85% ORR was seen [150]. The gene discussed is RET; the disease is non-small cell lung carcinoma.